0001787306-24-000020.txt : 20240215
0001787306-24-000020.hdr.sgml : 20240215
20240215183610
ACCESSION NUMBER: 0001787306-24-000020
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240213
FILED AS OF DATE: 20240215
DATE AS OF CHANGE: 20240215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Burnett Patrick
CENTRAL INDEX KEY: 0001741987
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39186
FILM NUMBER: 24645288
MAIL ADDRESS:
STREET 1: C/O VERRICA PHARMACEUTICALS INC.
STREET 2: 10 NORTH HIGH STREET, SUITE 200
CITY: WEST CHESTER
STATE: PA
ZIP: 19380
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Arcutis Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001787306
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 812974255
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3027 TOWNSGATE ROAD
STREET 2: SUITE 300
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91361
BUSINESS PHONE: 805-418-5006
MAIL ADDRESS:
STREET 1: 3027 TOWNSGATE ROAD
STREET 2: SUITE 300
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91361
FORMER COMPANY:
FORMER CONFORMED NAME: Arcutis, Inc.
DATE OF NAME CHANGE: 20190905
4
1
wk-form4_1708040155.xml
FORM 4
X0508
4
2024-02-13
0
0001787306
Arcutis Biotherapeutics, Inc.
ARQT
0001741987
Burnett Patrick
C/O ARCUTIS BIOTHERAPEUTICS, INC.
3027 TOWNSGATE ROAD SUITE 300
WESTLAKE VILLAGE
CA
91361
0
1
0
0
See Remarks
0
Common Stock
2024-02-13
4
A
0
128000
A
213032
D
Common Stock
2024-02-13
4
A
0
9600
A
222632
D
Common Stock
2024-02-13
4
A
0
23550
A
246182
D
Common Stock
2024-02-13
4
A
0
27900
A
274082
D
Stock Option (right to buy)
25.89
2024-02-13
4
D
0
320000
D
2030-08-03
Common Stock
320000
0
D
Stock Option (right to buy)
32.44
2024-02-13
4
D
0
28800
D
2031-03-02
Common Stock
28800
0
D
Stock Option (right to buy)
17.67
2024-02-13
4
D
0
47100
D
2032-03-03
Common Stock
47100
0
D
Stock Option (right to buy)
15.82
2024-02-13
4
D
0
55800
D
2033-03-02
Common Stock
55800
0
D
On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on August 3, 2020, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in four equal quarterly installments commencing May 1, 2024.
On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2021, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024
On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2022, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024.
On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 2, 2023, and received in exchange for the option, these RSUs that vest in twelve equal quarterly installments commencing May 1, 2024.
The canceled option vested as to 1/4 of the total shares on August 1, 2021, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vesting on August 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
The canceled option vest as to 1/48 of the shares subject to the option vest on each monthly anniversary measured from March 3, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.
The canceled option vest as to 1/48 of the shares subject to the option vest on each monthly anniversary measured from March 1, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.
The canceled option vest as to 1/48 of the shares subject to the option vest on each monthly anniversary measured from March 1, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.
Reporting Person's title: Senior Vice President, Chief Medical Officer
/s/ John W. Smither, as Attorney-in-Fact for Patrick Burnett
2024-02-15